 |
| |
|
Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response In Clinical Trial
|
|
Posted by poley on Monday, February 08 @ 07:55:30 PST (7 reads)
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation. Similar to previously reported data from the initial lowest dose cohort of this phase I trial, the vaccine was found to be generally safe and well tolerated. While previously reported data showed significant cellular and humoral immune responses, data from this second, intermediate dose group highlighted a significantly increased and dose-related immune response specific to the antigens targeted by the vaccine.
Read More...
(Read More... | Score: 3)
|
|
Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella typhimurium and a killed vaccine completely protects chickens from H5N1 highly p
|
|
Posted by poley on Friday, February 05 @ 07:24:37 PST (17 reads)
H5N1 highly pathogenic avian influenza virus (HPAIV) has posed a great threat not only for poultry industry, but also for human health. However, an effective vaccine to provide full spectrum of protection is lacking in the poultry field. In the current study, a novel prime–boost vaccination strategy against H5N1 HPAIV was developed in which chickens were first orally immunized with a hemagglutinin (HA) DNA vaccine delivered by attenuated Salmonella typhimurium, followed by boosting with a killed vaccine. Chickens in the combined vaccination group, but not in single vaccination and control groups, were completely protected against disease following H5N1 HPAIV intranasal challenge with no clinical signs and virus shedding.
Read More...
(Read More... | Score: 0)
|
|
Clinical Trial Application for SCIB1 melanoma vaccine
|
|
Posted by poley on Tuesday, February 02 @ 13:04:36 PST (31 reads)
Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, was submitted to the Gene Therapy Advisory Committee (‘GTAC’) on 29 December 2009. In addition, Scancell and its partner Ichor Medical Systems (‘Ichor’) submitted parallel applications to the Medicines Division and to the Devices Division of the Medicines and Healthcare products Regulatory Agency (‘MHRA’) on 29 January 2010 requesting approvals for the clinical trial of SCIB1 and for the use of Ichor’s TriGrid™ electroporation delivery device to administer SCIB1 to participating patients, respectively.
Read More...
(Read More... | Score: 5)
|
|
Effect of VP28 DNA vaccine on white spot syndrome virus in Litopenaeus vannamei
|
|
Posted by poley on Monday, February 01 @ 07:23:05 PST (20 reads)
White spot syndrome virus (WSSV) occurs worldwide and causes high mortality and considerable economic damage to the shrimp farming industry. Considering the global environmental, the economic and sociological importance of shrimp farming, and the constraints of high intensity cultivation, development of novel control measures against the outbreak of WSSV become inevitable. In this study, we have explored the protective efficacy of DNA vaccination and tissue distribution of the recombinant plasmid in immunized Litopenaeus vannamei. The VP28 gene was cloned in the eukaryotic expression vector pVAX1, and the construct vector was named as lpv28. The protective effect of lpv28 against WSSV was evaluated in L. vannamei by injecting lpv28 construct and later challenging with WSSV. Expression of these proteins from the recombinant plasmids was confirmed in vitro by RT-PCR and Western blot analysis. The result of vaccination trials showed that a survival rate in shrimp vaccinated with lpv28 was 52.5% at most compared to control groups (100% mortality).
Read More...
(Read More... | Score: 4)
|
|
An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response
|
|
Posted by poley on Wednesday, January 27 @ 07:57:56 PST (44 reads)
Abstract
We investigated whether a combined DNA vaccine delivered together with the IL-15 gene (DNA-IL-15(+)) enhanced the immune response against Brucella abortus in mice. Mice vaccinated with DNA-IL-15(+) developed a robust humoral response; Brucella-specific antibodies exhibited a dominance of immunoglobulin G2a (IgG2a) over IgG1. Splenocytes from DNA-IL-15(+)-vaccinated mice induced significantly higher levels of IFN-γ (P < 0.01) and CD8+ T cell response (P < 0.01), suggesting induction of a T-helper-1-dominated immune response. In a specific cytotoxic-T-lymphocyte activity assay, DNA-IL-15(+) immunization elicited mainly CD8+ T cells, which mediate cytotoxicity, but also CD4+ T cells. In vivo depletion of T cell subsets showed that the DNA-IL-15(+)-induced protection against Brucella infection is mediated predominantly by CD8+ T cells, although CD4+ T cells also contribute. These data indicate that plasmid-delivered IL-15 increases the efficacy of the Brucella DNA vaccine.
Read More...
(Read More... | Score: 4)
|
|
Inovio Unveils Skin Electroporation Technology for Delivering DNA Vaccines
|
|
Posted by poley on Wednesday, January 27 @ 07:52:44 PST (40 reads)
SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, today unveiled its new clinical-grade, miniaturized electroporation device designed to be an easy-to-use, portable delivery product for DNA vaccines. Inovio believes the device may be used to inoculate large populations against infectious diseases such as influenza, dengue and malaria. This new skin electroporation technology has been used to deliver DNA vaccines in several preclinical animal models and generated strong, protective antibody responses, which are required to provide immunity against targeted diseases. Dr. Niranjan Sardesai, SVP, Research and Development, introduced this new technology and device in a presentation at Phacilitate Vaccine Forum Washington 2010 on Tuesday, January 26th, in Washington, DC.
Read More...
(Read More... | Score: 3)
|
|
Inovio Expands DNA Vaccine Intellectual Property License with University of Pennsylvania.
|
|
Posted by poley on Monday, January 25 @ 07:57:55 PST (49 reads)
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that it has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against pandemic influenza, Chikungunya, and foot-and-mouth disease. The amendment also encompasses new chemokine and cytokine molecular adjuvant technologies. The technology was developed in the University of Pennsylvania laboratory of Professor David B. Weiner, a pioneer in the field of DNA vaccines, and chairman of Inovio’s scientific advisory board.
Read More...
(Read More... | Score: 4)
|
|
DNA vaccine therapy for melanoma in pets.
|
|
Posted by poley on Monday, January 25 @ 07:54:54 PST (47 reads)
Q: Can you tell me more about DNA vaccine therapy for digit melanoma?
A: The new DNA vaccine for melanoma in pets is made from human tyrosinase enzyme. It is only available through a licensed veterinary oncologist, so your veterinarian would not be able to administer it. The best advice I can give is to have your doctor refer you to a local cancer specialist and discuss if your pet is a candidate for the vaccine. I believe each injection of the vaccine costs between $300 and $500, and several are needed in addition to traditional chemotherapy or radiation therapy. The encouraging news is that the vaccine appears to give pets a longer life expectancy following diagnosis, in some cases doubling the life expectancy of the dog with melanoma.
Read More...
(Read More... | Score: 2)
|
|
Inovio Biomedical to Present at Partnering and Vaccine Conferences
|
|
Posted by poley on Wednesday, January 20 @ 07:07:55 PST (47 reads)
SAN DIEGO--(BUSINESS WIRE)-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. Avtar Dhillon, Executive Chairman, will present at the 8th Annual BioPartnering North America conference on Monday, January 25th, at 10:15 a.m. at the Westin Bayshore Resort in Vancouver, BC, Canada.
Dr. Niranjan Sardesai, SVP, Research and Development, will make a presentation entitled, "Case study: Therapeutic vaccines for HPV and HCV," at Phacilitate Vaccine Forum Washington 2010 on Tuesday, January 26th, at 4:15 p.m. at the Grand Hyatt in Washington, DC. He will also participate in a panel discussion regarding prophylactic and therapeutic vaccines at 4:35 p.m. on Tuesday, January 26th.
Read More...
(Read More... | Score: 3)
|
|
New vaccine-making company opens in Fargo
|
|
Posted by poley on Thursday, January 14 @ 12:37:03 PST (97 reads)
FARGO — Altravax, a new vaccine development company, has been launched in Fargo with a potential of creating 40 new jobs in five years.
Principles in the venture are Fargo-based entrepreneurs Michael Chambers, who launched vaccine development company Aldevron in 1998, and James Burgum, managing director of venture capital fund Arthur Ventures LLC.
Altravax has acquired the vaccine component of Maxygen, a Redwood City, Calif.-based biotechnology company founded in 1997.
The new company will initially have seven employees in Fargo and Sunnyvale, Calif., Chambers said. Six are former Maxygen vaccine team members.
Read More...
(Read More... | Score: 3)
|
| |
| |
